CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm

CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm

CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year. Read more >>

Share this post